Treatment of Cystoid Macular Edema with Octreotide

Abstract

Letters to the Editor are considered for publication (subject to editing and abridgment) provided they do not contain material that has been submitted or published elsewhere. Please note the following: •Your letter must be typewritten and triple-spaced. •Its text, not including references, must not exceed 400 words (please include a word count). •It must have no more than five references and one figure or table.

Somatostatin and somatostatin receptors in retinal diseases

“…Differential SST expression was found with RT-PCR of the rat eye (13). SST subtypes 2 and 4 were the major subtypes expressed predominately in the rat iris/ciliary body and retina respectively; SST 1 , SST 3 and SST 5 were preferentially expressed in the posterior eye, including the retina. Recently, we performed an immunohistochemical study of human retinas, using a rabbit polyclonal antiserum directed against SST 1 and SST 2A .…”

“…In this patient the visual acuity increased significantly after octreotide treatment. Interruption of octreotide treatment resulted subsequently in a decreased visual acuity (3). In addition to dominant CME, we have treated 10 patients with refractory CME secondary to uveitis with subcutaneous octreotide or Sandostatin-LAR.…”

Octreotide inhibits growth factor-induced bovine choriocapillary endothelial cells in vitro

“…Octreotide -an analogue of somatostatin -has recently been found to have possibly advantageous effect in patients with choroidal neovascular membranes [17].…”

Deficit of Somatostatin in the Vitreous Fluid of Patients With Diabetic Macular Edema

“…Systemic administration of SST analogues has been successfully used as a treatment of DME in isolated cases (23)(24)(25), but thus far there are no large series demonstrating its usefulness. The bloodretinal barrier is a limiting factor for systemic administration of drugs that should target the retina.…”